Drugs / Protamin
last change Apr 2024 re-read 2 minutes ago

Protamin

Developed for
prostate carcinoma · blood coagulation disease · cardiac valvular defect
Investigated by
University Hospital Tuebingen

Trials 1 · a red edge is where a trial was stopped

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT02452307 Apr 2004 → Oct 2017 prostate carcinoma University Hospital Tuebingen Unknown No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 41 trial
Phase 4 NCT02675647 Background Dec 2015 → Dec 2016 morbid obesity University Hospital, Strasbourg, France Completed No outcome recorded
Phase not applicable1 trial
NCT06154018 Comparator Mar 2023 → Apr 2024 blood coagulation disease, cardiac valvular defect, heart valve disorder University of Ioannina Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Protamin ClinicalTrials.gov intervention name — accepted as the source's own label NCT02675647
2

NCT02452307

NCT06154018

Route Subcutaneous subcutaneousNCT02452307